Table 1 Baseline characteristics of the two study groups
Variable | NSTE-ACS (no. = 100) | CSA (no. = 100) | P value* |
|---|---|---|---|
Age,(years) | 59 ± 6 | 58 ± 5 | 0.601 |
Males | 66 (66) | 64 (64) | 0.598 |
Hypertension | 55 (55) | 51 (51) | 0.544 |
Diabetes mellitus | 30 (30) | 32 (32) | 0.598 |
Dyslipidemia | 58 (58) | 56 (56) | 0.568 |
Smoking | 37 (37) | 40 (40) | 0.696 |
Family history of CAD | 17 (17) | 18 (18) | 0.589 |
Body mass index (kg/m2) | 25 ± 2 | 26 ± 3 | 0.654 |
Left ventricle ejection fraction (%) | 51 ± 5 | 54 ± 3 | 0.543 |
Left ventricle end diastolic diameter (mm) | 56 ± 4 | 53 ± 4 | 0.435 |
Left ventricle end systolic diameter (mm) | 39 ± 3 | 37 ± 5 | 0.556 |
Wall motion score index | 1.45 ± 0.3 | 1.42 ± 0.22 | 0.476 |
Pre-enrollment medications | |||
Beta blockers | 12 (20) | 14 (24) | 0.589 |
Calcium antagonists | 11 (18) | 9 (16) | 0.597 |
Angiotensin converting enzyme inhibitors/angiotensin receptor blockers | 18 (30) | 17 (29) | 0.644 |
Oral nitrates | 13 (22) | 12 (21) | 0.688 |